drugset
drugset / Trial / NCT05021770

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

NCT05021770 ↗

Phase 1/2 Unknown 29 enrolled Huiqiang Huang Guangdong 999 Brain Hospital · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study was to investigate the maximum tolerated dose and efficacy of Orelabrutinib combined with Thiotepa in refractory and relapsed primary central nervous system lymphoma (PCNSL).

Timeline

Start
2021-12
Primary completion
2022-12
Completion
2024-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Orelabrutinib Small molecule 150 mg Oral
Subject Orelabrutinib Small molecule 200 mg Oral
Subject Thiotepa Other / unclassified 30 mg/m2 Intravenous

Indications

non-Hodgkin lymphoma primary central nervous system lymphoma